09:21 EST Acelyrin (SLRN) sinks 39% to $2.12 after thyroid eye disease data update
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLRN:
- Wedbush stays positive on Viridian shares after Acelyrin data
- Acelyrin price target lowered to $6 from $8 at H.C. Wainwright
- Acelyrin announces additional lonigutamab data, design for LONGITUDE program
- Acelyrin price target lowered to $5 from $6 at Morgan Stanley
- Acelyrin price target lowered to $13 from $15 at Wells Fargo